Real-life use of remdesivir in hospitalized patients with COVID-19

被引：15

作者：

Garcia-Vidal, Carolina ^{[1
]}

Meira, Fernanda ^{[1
]}

Duenas, Gerard ^{[1
]}

Puerta-Alcalde, Pedro ^{[1
]}

Garcia-Pouton, Nicole ^{[1
]}

Chumbita, Mariana ^{[1
]}

Cardozo, Celia ^{[1
]}

Hernandez-Meneses, Marta ^{[1
]}

Alonso-Navarro, Rodrigo ^{[1
]}

Rico, Veronica ^{[1
]}

Aguero, Daiana ^{[1
]}

Bodro, Marta ^{[1
]}

Morata, Laura ^{[1
]}

Jordan, Carlota ^{[1
]}

Lopera, Carlos ^{[1
]}

Ambrosioni, Juan ^{[1
]}

Segui, Ferran ^{[1
]}

Grafia, Nacho ^{[1
]}

Castro, Pedro ^{[2
]}

Garcia, Felipe ^{[1
]}

Mensa, Josep ^{[1
]}

Martinez, Jose Antonio ^{[1
]}

Sanjuan, Gemma ^{[1
,3
]}

Soriano, Alex ^{[1
]}

Cozar-Llisto, Alberto

机构：

[1] Univ Barcelona, Hosp Clin Barcelona IDIBAPS, Dept Infect Dis, Barcelona, Spain

[2] Univ Barcelona, Hosp Clin, Med Intens Care Unit, IDIBAPS, Barcelona, Spain

[3] Hosp Clin Barcelona, Comp Syst Unit, Barcelona, Spain

来源：

REVISTA ESPANOLA DE QUIMIOTERAPIA | 2021年 / 34卷 / 02期

关键词：

Antivirals; COVID-19; outcome; remdesivir;

D O I：

10.37201/req/018.2021

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Objective. Controversial results on remdesivir efficacy have been reported. We aimed to report our real-life experience with the use of remdesivir from its availability in Spain. Methods. We performed a descriptive study of all patients admitted for >= 48 hours with confirmed COVID-19 who received remdesivir between the 1st of July and the 30th of September 2020. Results. A total of 123 patients out of 242 admitted with COVID-19 at our hospital (50.8%) received remdesivir. Median age was 58 years, 61% were males and 56.9 % received at least one anti-inflammatory treatment. No adverse events requiring remdesivir discontinuation were reported. The need of intensive care unit admission, mechanical ventilation and 30-days mortality were 19.5%, 7.3% and 4.1%, respectively. Conclusion. In our real-life experience, the use of remdesivir in hospitalized patients with COVID-19 was associated with a low mortality rate and good safety profile.

引用

页码：136 / 140

页数：5

共 50 条

[21] Use of Remdesivir in Patients with SARS-CoV-2 Pneumonia in a Real-Life Setting during the Second and Third COVID-19 Epidemic Waves
Marocco, Raffaella
Del Borgo, Cosmo
Tortellini, Eeva
Garattini, Silvia
Carraro, Anna
Di Trento, Daniela
Gasperin, Andrea
Grimaldi, Alessandra
Tieghi, Tiziana
Belvisi, Valeria
Kertusha, Blerta
Guardiani, Mariasilvia
Zuccala, Paola
Fegatelli, Danilo Alunni
Spagnoli, Alessandra
Lichtner, Miriam
[J]. VIRUSES-BASEL, 2023, 15 (04):
[22] Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience
Campogiani, Laura
Iannetta, Marco
Di Lorenzo, Andrea
Zordan, Marta
Pace, Pier Giorgio
Coppola, Luigi
Compagno, Mirko
Malagnino, Vincenzo
Teti, Elisabetta
Andreoni, Massimo
Sarmati, Loredana
[J]. MICROORGANISMS, 2023, 11 (02)
[23] Real-life experience with remdesivir for treatment of COVID-19 among older adults: a multicentre retrospective study
Margalit, Ili
Tiseo, Giusy
Ripa, Marco
Borghi, Vanni
Green, Hefziba
Prendki, Virginie
Riccardi, Niccolo
Perego, Giovanni Battista
Grembiale, Alessandro
Galli, Laura
Tinelli, Marco
Castagna, Antonella
Mussini, Cristina
Falcone, Marco
Yahav, Dafna
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (06) : 1505 - 1509
[24] Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia
Alex, Ruth
Gulam, Shabaz Mohiuddin
Kumar, Kiran
[J]. ADVANCES IN VIROLOGY, 2022, 2022
[25] Real-life evaluation of a COVID-19 rapid antigen detection test in hospitalized children
Eleftheriou, Irini
Dasoula, Foteini
Dimopoulou, Dimitra
Lebessi, Evangelia
Serafi, Eftihia
Spyridis, Nikos
Tsolia, Maria
[J]. JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (10) : 6040 - 6044
[26] Comparison of Safety and Outcomes Related to Remdesivir Use Among Dialysis Patients Hospitalized with COVID-19
Zaki, Kirollos E.
Huang, Cheng-Wei
Zhou, Hui
Chung, Joanie
Selevan, David C.
Rutkowski, Mark P.
Sim, John J.
[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 102 - 102
[27] Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study
Russo, Gianluca
Solimini, Angelo
Zuccala, Paola
Zingaropoli, Maria Antonella
Carraro, Anna
Pasculli, Patrizia
Perri, Valentina
Marocco, Raffaella
Kertusha, Blerta
Del Borgo, Cosmo
Del Giudice, Emanuela
Fondaco, Laura
Tieghi, Tiziana
D'Agostino, Claudia
Oliva, Alessandra
Vullo, Vincenzo
Ciardi, Maria Rosa
Mastroianni, Claudio Maria
Lichtner, Miriam
[J]. PLOS ONE, 2021, 16 (09):
[28] Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19
Falcone, Marco
Suardi, Lorenzo Roberto
Tiseo, Giusy
Barbieri, Chiara
Giusti, Lisa
Galfo, Valentina
Forniti, Arianna
Caroselli, Claudio
Della Sala, Leonardo
Tempini, Sara
Okoye, Chukwuma
Monzani, Fabio
Menichetti, Francesco
[J]. CLINICAL THERAPEUTICS, 2022, 44 (03) : 364 - 373
[29] Use of remdesivir for COVID-19 in patients with hematologic cancer
Martin-Onraet, Alexandra
Barrientos-Flores, Corazon
Vilar-Compte, Diana
Perez-Jimenez, Carolina
Alatorre-Fernandez, Pamela
[J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) : 2231 - 2238
[30] A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel
Goldberg, Elad
Ben Zvi, Haim
Sheena, Liron
Sofer, Summer
Krause, Ilan
Sklan, Ella H.
Shlomai, Amir
[J]. CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (06) : 917.e1 - 917.e4

← 1 2 3 4 5 →